Amarin reported $16.89M in Cost of Sales for its fiscal quarter ending in March of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amarin USD 16.89M 18.51M Mar/2025
AstraZeneca USD 2.47B 232M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
Halozyme Therapeutics USD 64.12M 15.72M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Novartis USD 3.32B 95M Jun/2025